B-cell lymphoma proteins 3D structures
From Proteopedia
(Difference between revisions)
| (One intermediate revision not shown.) | |||
| Line 14: | Line 14: | ||
**[[2mej]] - hBcl-xL + p53 - NMR<br /> | **[[2mej]] - hBcl-xL + p53 - NMR<br /> | ||
**[[6lhd]] - hBcl-xL/p53 <br /> | **[[6lhd]] - hBcl-xL/p53 <br /> | ||
| - | **[[1ysg]], [[3sp7]], [[3spf]], [[3wiz]], [[4tuh]], [[3zln]], [[3zk6]], [[3zlo]], [[3zlr]], [[4c52]], [[4c5d]], [[2yxj]], [[4qnq]], [[4qvx]], [[6rnu]], [[6vwc]], [[7jgv]], [[7jgw]] - hBcl-xL + inhibitor<br /> | + | **[[1ysg]], [[3sp7]], [[3spf]], [[3wiz]], [[4tuh]], [[3zln]], [[3zk6]], [[3zlo]], [[3zlr]], [[4c52]], [[4c5d]], [[2yxj]], [[4qnq]], [[4qvx]], [[6rnu]], [[6vwc]], [[7jgv]], [[7jgw]], [[7lh7]] - hBcl-xL + inhibitor<br /> |
| + | **[[7xgf]] - hBcl-xL + inhibitor protein<br /> | ||
**[[3inq]] - hBcl-xL (mutant) + inhibitor<br /> | **[[3inq]] - hBcl-xL (mutant) + inhibitor<br /> | ||
**[[2w3l]] – hBcl-xL + quinoline derivative<br /> | **[[2w3l]] – hBcl-xL + quinoline derivative<br /> | ||
| Line 41: | Line 42: | ||
**[[5b1z]] - hBcl-xL + BHX BH3 domain<br /> | **[[5b1z]] - hBcl-xL + BHX BH3 domain<br /> | ||
**[[4z9v]] - hBcl-xL + TCTP BH3 domain<br /> | **[[4z9v]] - hBcl-xL + TCTP BH3 domain<br /> | ||
| + | **[[7wjh]] - hBcl-xL + Pxt1 BH3 domain<br /> | ||
**[[6dcn]], [[6dco]] - hBcl-xL + Beclin-1 BH3 domain<br /> | **[[6dcn]], [[6dco]] - hBcl-xL + Beclin-1 BH3 domain<br /> | ||
**[[2p1l]] - hBcl-xL (mutant) + Beclin-1 BH3 domain<br /> | **[[2p1l]] - hBcl-xL (mutant) + Beclin-1 BH3 domain<br /> | ||
| Line 59: | Line 61: | ||
**[[4aq3]], [[4man]], [[5jsn]], [[4ieh]], [[6gl8]], [[6qgg]], [[6qgj]], [[6qgk]], [[7jmt]] – hBcl-2 + inhibitor<br /> | **[[4aq3]], [[4man]], [[5jsn]], [[4ieh]], [[6gl8]], [[6qgg]], [[6qgj]], [[6qgk]], [[7jmt]] – hBcl-2 + inhibitor<br /> | ||
**[[4lvt]], [[4lxd]], [[6o0k]], [[6o0m]], [[6o0o]], [[6o0p]] – hBcl-2 (mutant) + inhibitor<br /> | **[[4lvt]], [[4lxd]], [[6o0k]], [[6o0m]], [[6o0o]], [[6o0p]] – hBcl-2 (mutant) + inhibitor<br /> | ||
| - | **[[7lhb]] – hBcl-2 + drug<br /> | + | **[[7lhb]] – hBcl-2 (mutant) + drug<br /> |
**[[5fcg]] – hBcl-2 (mutant) + HBX BH3 domain<br /> | **[[5fcg]] – hBcl-2 (mutant) + HBX BH3 domain<br /> | ||
**[[2xa0]] – hBcl-2 residues 1-207 + apoptosis regulator Bax BH3 domain<br /> | **[[2xa0]] – hBcl-2 residues 1-207 + apoptosis regulator Bax BH3 domain<br /> | ||
| Line 74: | Line 76: | ||
**[[2voh]] - mBcl-2A1 + Bak BH3 peptide <br /> | **[[2voh]] - mBcl-2A1 + Bak BH3 peptide <br /> | ||
**[[2voi]] - mBcl-2A1 + BID BH3 peptide <br /> | **[[2voi]] - mBcl-2A1 + BID BH3 peptide <br /> | ||
| - | |||
*Bcl-3 | *Bcl-3 | ||
| Line 127: | Line 128: | ||
**[[2k7w]] – hBax + BIM BH3 peptide - NMR<br /> | **[[2k7w]] – hBax + BIM BH3 peptide - NMR<br /> | ||
**[[4zie]], [[4zif]], [[4zig]], [[4zih]], [[4zii]], [[5vww]] – hBax (mutant) + BIM BH3 peptide<br /> | **[[4zie]], [[4zif]], [[4zig]], [[4zih]], [[4zii]], [[5vww]] – hBax (mutant) + BIM BH3 peptide<br /> | ||
| + | **[[6wgz]] – hBax + MBP + Bak BH3 peptide<br /> | ||
**[[4bd2]] – hBax (mutant) + BID BH3 peptide<br /> | **[[4bd2]] – hBax (mutant) + BID BH3 peptide<br /> | ||
**[[5w5z]], [[5w5x]] – hBax (mutant) + antibody<br /> | **[[5w5z]], [[5w5x]] – hBax (mutant) + antibody<br /> | ||
| Line 139: | Line 141: | ||
**[[5fmi]], [[4u2u]], [[5vx1]] – hBak (mutant)<br /> | **[[5fmi]], [[4u2u]], [[5vx1]] – hBak (mutant)<br /> | ||
**[[4u2v]] – hBak/GFP<br /> | **[[4u2v]] – hBak/GFP<br /> | ||
| + | **[[7ofm]], [[7ofo]] – hBak transmembrane helix - NMR<br /> | ||
**[[3qbr]] - hBak + sjA<br /> | **[[3qbr]] - hBak + sjA<br /> | ||
**[[6uxm]], [[6uxn]], [[6uxo]], [[6uxp]], [[6uxq]], [[6uxr]] - hBak + inhibitor<br /> | **[[6uxm]], [[6uxn]], [[6uxo]], [[6uxp]], [[6uxq]], [[6uxr]] - hBak + inhibitor<br /> | ||
| Line 145: | Line 148: | ||
**[[5vwv]] - hBak (mutant)+ BIM BH3 domain<br /> | **[[5vwv]] - hBak (mutant)+ BIM BH3 domain<br /> | ||
**[[2m5b]] - hBak + BID BH3 domain - NMR<br /> | **[[2m5b]] - hBak + BID BH3 domain - NMR<br /> | ||
| + | **[[7m5c]] – hBak + Bak BH3 peptide<br /> | ||
| + | **[[7m5a]], [[7m5b]] – hBak + M3W5 BID<br /> | ||
| + | **[[7lk4]] – hBak (mutant) + antibody<br /> | ||
**[[6mcy]] – mBak<br /> | **[[6mcy]] – mBak<br /> | ||
| Line 157: | Line 163: | ||
**[[2nl9]] – hBim + Mcl-1<br /> | **[[2nl9]] – hBim + Mcl-1<br /> | ||
**[[6x8o]] – hBim BH3 peptide<br /> | **[[6x8o]] – hBim BH3 peptide<br /> | ||
| + | |||
| + | *Bcl-2-like protein 15 | ||
| + | |||
| + | **[[7ccl]], [[7ccm]] - hBcl-2-L-15<br /> | ||
Mcl-1 (Bcl-2-like protein 3 or Myeloid cell leukemia-1) | Mcl-1 (Bcl-2-like protein 3 or Myeloid cell leukemia-1) | ||
| Line 167: | Line 177: | ||
**[[4wmu]], [[4wmt]] - hMcl-1/MBP (mutant) + ligand<br /> | **[[4wmu]], [[4wmt]] - hMcl-1/MBP (mutant) + ligand<br /> | ||
**[[4wgi]] - hMcl-1/MBP (mutant) + macrolactam<br /> | **[[4wgi]] - hMcl-1/MBP (mutant) + macrolactam<br /> | ||
| - | **[[3wix]], [[3wiy]], [[4oq5]], [[4oq6]], [[4hw2]], [[4hw3]], [[4hw4]], [[4wmr]], [[4zbf]], [[4zbi]], [[5fc4]], [[5fdo]], [[5fdr]], [[5iez]], [[5if4]], [[5jsb]], [[5ku9]], [[5vkc]], [[6b4l]], [[6b4u]], [[6bw2]], [[6bw8]], [[6fs1]], [[6fs2]], [[6ne5]], [[6o4u]], [[6o6f]], [[6oqb]], [[6oqc]], [[6oqd]], [[6oqn]], [[6p3p]], [[6qgd]], [[6qfq]], [[6qyp]], [[6qz5]], [[6qz6]], [[6qz8]], [[6qzb]], [[6u63]], [[6u64]], [[6u65]], [[6u67]], [[6u6f]], [[6ud2]], [[6udi]], [[6udt]], [[6udu]], [[6udv]], [[6udx]], [[6udy]], [[6ybg]] - hMcl-1 residues 174-324 + inhibitor<br /> | + | **[[3wix]], [[3wiy]], [[4oq5]], [[4oq6]], [[4hw2]], [[4hw3]], [[4hw4]], [[4wmr]], [[4zbf]], [[4zbi]], [[5fc4]], [[5fdo]], [[5fdr]], [[5iez]], [[5if4]], [[5jsb]], [[5ku9]], [[5vkc]], [[6b4l]], [[6b4u]], [[6bw2]], [[6bw8]], [[6fs1]], [[6fs2]], [[6ne5]], [[6o4u]], [[6o6f]], [[6oqb]], [[6oqc]], [[6oqd]], [[6oqn]], [[6p3p]], [[6qgd]], [[6qfq]], [[6qyp]], [[6qz5]], [[6qz6]], [[6qz8]], [[6qzb]], [[6u63]], [[6u64]], [[6u65]], [[6u67]], [[6u6f]], [[6ud2]], [[6udi]], [[6udt]], [[6udu]], [[6udv]], [[6udx]], [[6udy]], [[6ybg]], [[7nb4]], [[7nb7]] - hMcl-1 residues 174-324 + inhibitor<br /> |
| + | **[[7xge]], [[7xgg]] - hMcl-1 residues 174-324 + protein inhibitor<br /> | ||
**[[6ovc]] - hMcl-1 residues 174-324 + inhibitor - NMR<br /> | **[[6ovc]] - hMcl-1 residues 174-324 + inhibitor - NMR<br /> | ||
**[[6qxj]], [[6qyk]], [[6qyl]], [[6qyn]], [[6qyo]], [[6qz7]], [[6ybj]], [[6ybk]], [[6ybl]] - hMcl-1 residues 174-324/MBP + inhibitor<br /> | **[[6qxj]], [[6qyk]], [[6qyl]], [[6qyn]], [[6qyo]], [[6qz7]], [[6ybj]], [[6ybk]], [[6ybl]] - hMcl-1 residues 174-324/MBP + inhibitor<br /> | ||
| Line 196: | Line 207: | ||
**[[2o42]], [[2jbx]] – MvM11L – Myxoma virus<br /> | **[[2o42]], [[2jbx]] – MvM11L – Myxoma virus<br /> | ||
| - | **[[2jby]] – MvM11L + | + | **[[2jby]] – MvM11L + Bak <br /> |
**[[3dvu]], [[3bl2]], [[4mi8]] – M11 + Beclin-1 – Murid herpesvirus<br /> | **[[3dvu]], [[3bl2]], [[4mi8]] – M11 + Beclin-1 – Murid herpesvirus<br /> | ||
Current revision
3D structures of B-cell lymphoma proteins
Updated on 27-October-2022
Mcl-1 (Bcl-2-like protein 3 or Myeloid cell leukemia-1)
